Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT-02287 in Parkinson's Disease
NCT06732180Phase 1Recruiting
- Sponsor
- Gain Therapeutics
- Start
- Feb 2025
- Primary completion
- Nov 2025
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rexaceract in Parkinson's disease (PD), sponsored by Gain Therapeutics. Primary endpoints: Incidence, nature, relationship to investigational product, and severity of adverse events at Day 105 and Incidence of clinically significant findings for clinical laboratory evaluations, physical and neurological examinations, body weight, vital signs measurements, 12-lead electrocardiograms, C-SSRS at Day 105. Started Feb 2025; status: recruiting.
02
Drugs
rexaceract
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06732180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732180.